Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema

Figure 2

Spectral-domain optical coherence tomography scans of both the eyes (OU) showing the presence of cystoid macular edema (CME) at baseline (a, b). One month after intravitreal brolucizumab therapy, the patient demonstrated a bilateral reduction in the CME (c, d).

(a)

(b)

(c)

(d)